

厚生労働行政推進調査事業費補助金（肝炎等克服政策研究事業）
分担研究報告書

肝がん・重度肝硬変の治療に係るガイドラインの作成等に資する研究

工藤 正俊 近畿大学医学部 消化器内科 主任教授
(研究協力者) 西田 直生志 近畿大学医学部 消化器内科 准教授

研究要旨

データ収集プラットフォーム作成

A. 研究目的

肝癌重度肝硬変のうち特に肝癌の治療に
係る各国の研究状況と診療の実態調査。

B. 研究方法

肝癌に関する各種国際学会に出席し、各國
における各ステージにおける治療成績、治
療の適応などにおいて我が国と比較を行
った。

C. 研究結果

日本の肝癌のサーベイランス、診断、治療
は他国と比べて優れているということ、お
よび治療方針なども他国と大きく異なっ
ていることが明らかとなった。

D. 考察

今後日本において肝癌や重度肝硬変にお
いて効率的に進めるためには、患者の経済
的サポートも重要と考えられた。

E. 結論

日本の肝癌の診療レベルは世界的に優れ
ているが、更に患者の経済的援助が必要と
考えられた。

F. 健康危険情報

なし

G. 研究発表

1) 論文発表

- Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M: Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. *J Hepatol* 2020;72:307-319.
- Sakurai T, Nishiyama H, Nagai T, Goto S, Ogata H, Kudo M: Deficiency of Gankyrin in the small intestine is associated with augmented colitis accompanied by altered bacterial composition of intestinal microbiota. *BMC Gastroenterol* 2020;20:12.
- Matsui S, Kashida H, Nomura K, Komeda Y, Kudo M: Multiple gastrointestinal stromal tumors of the duodenum associated with neurofibromatosis type. *Advanced Research in Gastroenterol & Hepatol (ARGH)* 14, 2020 (doi: 10.0.74.136/ARGH.2020.14.555889).
- Takashima K, Matsui S, Komeda Y, Nagai T, Sakurai T, Kashida H, Kudo M: Endoscopic sclerotherapy under balloon-assisted enteroscopy for hemorrhagic jejunal varices

- after choledocho-jejunostomy. *Endoscopy* 2020; 52(2):E41-E42.
4. Kudo M: Management of hepatocellular carcinoma in Japan: Current trends. *Liver Cancer* 2020;9:1-5.
 5. Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TRJ, López López C, Daniele B, Misir S, Ren M, Izumi N, Qin S, Finn RS: Effects of subsequent systemic anticancer medication following first-line lenvatinib: A post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. *Liver Cancer* 2020;9:93-104.
 6. Morita M, Ogawa C, Omura A, Noda T, Kubo A Matsunaka T, Tamaki H, Shibatoge M, Seno H, Minami Y, Ueshima K, Sakurai T, Nishida N, Kudo M: The efficacy of Sonazoid-enhanced ultrasonography in decision-making for liver abscess treatment. *Intern Med* 2020;59:471-477.
 7. Kanemura H, Hayashi H, Hagiwara S, Otani T, Haratani K, Yonesaka K, Ito A, Kudo M, Nakagawa K: Severe immune-related hepatitis treated with plasma exchange. *J Thorac Oncol* 2020;15:e39-e42.
 8. Aoki T, Kubota K, Hasegawa K, Kubo S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M, Liver Cancer Study Group of Japan: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. *Br J Surg* 2020;107:113-120.
 9. Aoki T, Kubota K, Kubo S, Kudo M: Author response to: comment on: "Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma". *Br J Surg* 2020;107:465.
 10. Aoki T, Kubota K, Kubo S, Kudo M: Author response to: comment on: "Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma". *Br J Surg* 2020;107:470.
 11. Minaga K, Takenaka M, Yamao K, Kamata K, Omoto S, Nakai A, Yamazaki T, Okamoto A, Ishikawa R, Yoshikawa T, Chiba Y, Watanabe T, Kudo M: Clinical utility of treatment method conversion during single-session endoscopic ultrasound-guided biliary drainage. *World J Gastroenterol* 2020;26:947-959.
 12. Hiraoka A, Kumada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Yokohama K, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, on behalf of the Real-Life Practice Experts for HCC (RELPEC) study group and HCC 48 Group: Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib. *Liver Cancer* 2020;9:73-83.
 13. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yao T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL, for the KEYNOTE-240 investigators: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase 3 trial. *J Clin Oncol* 2020;38:193-202.
 14. Yamao K, Watanabe T, Kudo M: Response to the letter to the editor 'Reply to "Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX":

- A Single-center Retrospective Study” by Dr. Peng Chen’. Intern Med 2020;59:879.
15. Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H: REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 2020;55:113-122.
 16. Takenaka M, Minaga K, Kamata K, Yamao K, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Komeda Y, Sakurai T, Watanabe T, Nishida N, Kwon C, Jeong S, Lee TH, Kudo M: Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven method) in patients with surgically altered gastrointestinal anatomy (with video). Surg Endosc 2020;34:1432-1441.
 17. Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Takayama T: Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2020;50:15-46.
 18. Minami Y, Minami T, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M: Radiofrequency ablation for hepatocellular carcinoma: clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. Hepatol Res 2020;50:67-74.
 19. Fukami Y, Kaneoka Y, Maeda A, Kumada T, Tanaka J, Aikata T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M, Liver Cancer Study Group of Japan: Liver resection for multiple hepatocellular carcinomas: A Japanese nationwide survey. Ann Surg, 2020 [epub ahead of print].
 20. Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ: Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: A response-based approach. Hepatology, 2020[Epub ahead of print].
 21. Takenaka M, Nakai A, Kudo M: Novel concept of bared type metallic stent for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction (with video). J Hepato-Bil-Pan Sci, 2020[Epub ahead of print].
 22. Masaki S, Watanabe T, Minaga K, Kamata K, Komeda Y, Kimura M, Kudo M: Possible involvement of autophagy in esophageal ulcers in anorexia nervosa. Clin J Gastroenterol, 2020[Epub ahead of print].
 23. Morimoto D, Hyodo T, Kamata K, Kadoba T, Itoh M, Fukushima H, Chiba Y, Takenaka M, Mochizuki T, Ueda Y, Miyagoshi K, Kudo M, Ishii K: Navigator-triggered and breath-hold 3D MRCP using compressed sensing: image quality and method selection factor assessment abdominal radiology. Abdom Radiol, 2020[Epub ahead of print].
 24. Yamao K, Takenaka M, Ogura T, Hashimoto H, Matsumoto H, Yamamoto M, Ikeura T, Kurita A, Li ZL, Shiomi H, Chiba Y, Kudo M, Sanuki

- T: Utility and safety of a novel fully covered metal stent in unresectable distal malignant biliary obstruction. *Digest Dis Sci*, 2020[*Epub ahead of print*].
25. Komeda Y, Watanabe T, Kudo M: Requirement of additional surgery after non-curative endoscopic submucosal dissection for early colorectal cancer. *J Invest Surg* 2020;30:1-2.
 26. Hiraoka A, Kumada T, Tada T, Fukunishi S, Atsukawa M, Hirooka A, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Toyoda H, Ohama H, Tsutsui A, Itokawa N, Hayama K, Arai T, Imai M, Nakamura S, Michitaka K, Hiasa Y, Kudo M, Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group: Nutritional index as prognostic indicator in patients receiving lenvatinib treatment for unresectable hepatocellular carcinoma. *Oncology* 2020;98:295-302.
 27. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y, on behalf of the TACTICS study group: Randomised, multicentre prospective trial of transarterial chemoembolization (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma. *Gut*, 2020[*Epub ahead of print*].
 28. Yoshida S, Matsumura M, Maekawa K, Minaga K, Kamata K, Nozawa M, Watanabe T, Kudo M: Recurrent abdominal pain caused by nephroptosis. *Clin J Gastroenterol*, 2020[*Epub ahead of print*].
 29. Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX: Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. *J Gastroenterol*, 2020[*Epub ahead of print*].
 30. Yoshida A, Minaga K, Takeda O, Hanno H, Takayanagi S, Dozaiku T, Kudo M: Successful biliary cannulation using a novel rotatable sphincterotome in a patient with situs inversus totalis. *Endoscopy*, 2020[*Epub ahead of print*].
 31. Sakurai T, Nishida N, Kudo M: Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents. *Hepatobil Surg Nutr*, 2020[*Epub ahead of print*].
 32. Kaibori M, Yoshii K, Yokota I, Hasegwa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of Japan: Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. *Ann Surg* 2019;269:692-699.
 33. Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T, Ishikawa T, Seike M, Katsume T, Ochiai T, Kimura K, Fukuhara T, Kano T, Nagata T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M: Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenic undergoing invasive procedures. *Clin Gastroenterol Hepatol* 2019;17:1192-1200.
 34. Hidaka H, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O,

- Yamashita T, Yokosuka O, Morita S, Arioka H, Kudo M, Arai Y: Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). *Med Oncol* 2019;36:52.
35. Tanaka H, Matsui S, Kashida H, Kudo M: Endoscopic submucosal dissection of duodenal adenocarcinoma arising from Brunner's gland. *Ann Gastroenterol* 20019;32:316.
36. Kono M, Sakurai T, Okamoto K, Masaki S, Nagai T, Komeda Y, Kamata K, Minaga K, Yamao K, Takenaka M, Watanabe T, Nishida N, Kudo M: Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis. *Intern Med* 2019;58:1263-1266.
37. Takeda H, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, Osaki Y, Kudo M: Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion. *Hepatol Res* 2019;49:594-599.
38. Itonaga M, Kitano M, Hatamaru K, Tamura T, Nuta J, Kawaji Y, Takenaka M, Minaga K, Kudo M, Ogura T, Higuchi K, Chiba Y: Endoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: a prospective multicenter study. *Dig Endosc* 2019;31:291-298.
39. Minaga K, Watanabe T, Chung H, Kudo M: Autoimmune hepatitis and IgG4-related disease. *World J Gastroenterol* 2019;25:2308-2314.
40. Minaga K, Watanabe T, Kamata K, Takenaka M, Yasukawa S, Kudo M: The IFN- α -IL-33 axis as possible biomarkers in IgG4-related disease. *Am J Gastroenterol* 2019;114:1002-1003.
41. Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX: Rationale 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. *Future Oncol* 2019;15:1811-1822.
42. Takenaka M, Yoshikawa T, Okamoto A, Nakai A, Minaga K, Yamao K, Kudo M: Novel sphincterotomy device that orientates blade along the axis of the bile duct in patients with Roux-en-Y anastomosis. *Endoscopy* 2019;51:E132-E134.
43. Hara A, Kamata K, Takenaka M, Chikugo T, Kudo M: Intracystic papillary neoplasm preoperatively diagnosed by high-quality cytology derived from endoscopic nasogallbladder drainage. *Gastrointest Endosc* 2019;89:1257-1259.
44. Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S: Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. *J Gastroenterol* 2019;54:558-570.
45. Okamoto A, Watanabe T, Kamata K, Minaga K, Kudo M: Recent updates on the relationship between cancer and autoimmune pancreatitis. *Intern Med* 2019;58:1533-1539.
46. Nishida N, Kudo M: Liver damage related to immune checkpoint inhibitor. *Hepatol Int* 2019;13:248-252.
47. Takenaka M, Okabe Y, Kudo M: Hemorrhage from metastasis of a 5-mm renal cell carcinoma lesions to the gallbladder detected by contrast-enhanced endoscopic ultrasonography. *Dig Liver Dis* 2019;51:743.

48. Zhu AX, Finn RS, Galle PR, Llovet JM, Kudo M: Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein. *Lancet Oncol* 2019;20:e191.
49. Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H, Minaga K, Kamata K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Enoki E, Inoue H, Matsumura I, Kudo M: Usefulness of ustekinumab for treating a case of myelodysplastic syndrome-associated inflammatory bowel disease. *Intern Med* 2019;58:2029-2033.
50. Yamao K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Hagiwara S, Sakurai T, Nishida N, Chiba Y, Watanabe T, Kudo M: Clinical safety and efficacy of secondary prophylactic pegylated G-CSF in advanced pancreatic cancer patients treated with mFOLFIRINOX: A single-center retrospective study. *Intern Med* 2019;58:1993-2002.
51. Kim SK, Kim SR, Imoto S, Shida N, Fujii Y, Fujii T, Kido M, Kinoshita H, Koma YI, Hayashi Y, Matsuoka T, Kudo M: Rapid and extensive intrahepatic metastatic recurrence of hepatocellular carcinoma with very small portal vein tumor thrombus after surgery and sustained virological response of HCV with direct-acting antivirals. *Pathol Int* 2019;69:306-308.
52. Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M: Switching from Entecavir to Tenofovir alafenamide versus maintaining Entecavir for chronic hepatitis B. *J Med Virol* 2019;91:1804-1810.
53. Yokomichi N, Nishida N, Umeda Y, Taniguchi F, Yasui K, Toshima T, Mori Y, Nyuya A, Tanaka T, Yamada T, Yagi T, Fujiwara T, Yamaguchi Y, Goel A, Kudo M, Nagasaka T: Heterogeneity of epigenetic and epithelial mesenchymal transition marks in hepatocellular carcinoma with keratin 19 proficiency. *Liver Cancer* 2019;8:239-254.
54. Kudo M: Immuno-Oncology therapy for hepatocellular carcinoma: Current status and ongoing trials. *Liver Cancer* 2019;8:221-238.
55. Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada K, Izumi N, Sumino Y, Ogawa C, Akazawa K, for the SELECTED Study Group, Japan: B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. *Liver Cancer* 2019;8:271-280.
56. Koizumi Y, Hirooka M, Tamaki N, Yada N, Nakashima O, Izumi N, Kudo M, Hiasa Y: New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. *Plos One* 2019;14:e0221548.
57. Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N: Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. *Cancers* 2019; 11(8). pii: E1084
58. Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M: Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: A multicenter study. *Cancers* 2019; 11(7). pii: E952.

59. Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcu CE, Piscaglia F, Sung MW: Urine protein: creatinine ratio vs 24-hour urine protein for proteinuria management: Analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. *Brit J Cancer* 2019;121:218-221.
60. Minami Y, Kudo M: Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need? *Hepatobil Surg Nutr (HBSN)* 2019;8:414-416.
61. Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E: Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: A propensity score analysis. *Liver Cancer* 2019;8:281-294.
62. Hirata D, Kashida H, Iwatate M, Tochio T, Teramoto A, Sano Y, Kudo M: Effective use of the Japan narrow band imaging expert team classification based on diagnostic performance and confidence level. *World J Clin Cases* 2019;7:2658-2665.
63. Takenaka M, Nakai A, Kudo M: Large balloon expansion method for re-intervention after endoscopic ultrasound-guided hepaticogastrostomy for stent obstruction. *Dig Endosc* 2019;31:e99-e100.
64. Kudo M, Ikeda M, Ueshima K, Sakamoto M, Shiina S, Tateishi R, Hasegawa K, Furuse J, Miyayama S, Murakami T, Yamashita T, Kokudo N: Response evaluation criteria in cancer of the liver (version 5) (RECICL 2019 revised version). *Hepatol Res* 2019;49:981-989.
65. Minaga K, Yoshikawa T, Yamashita Y, Akamatsu H, Ikenouchi M, Ishii T, Matsumoto H, Iwagami H, Nakatani Y, Hatamaru K, Takenaka M, Akamatsu T, Uenoyama Y, Watanabe T, Ono K, Chiba Y, Kudo M: Comparison of the diagnostic performance of newly designed 21-gauge and standard 22-gauge aspiration needles in patients with solid pancreatic masses. *Dig Dis Sci* 2019;64:2982-2991.
66. Minaga K, Ogura T, Shiomi H, Imai H, Hoki N, Takenaka M, Nishikiori H, Yamashita Y, Hisa H, Kato H, Kamada H, Okuda A, Sagami R, Hashimoto H, Higuchi K, Chiba Y, Kudo M, Kitano M: Comparison of the efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy and hepaticogastrostomy for malignant distal biliary obstruction: Multicenter randomized clinical trial. *Dig Endosc* 2019;31:575-582.
67. Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y: Objective response by mRECIST is an independent prognostic factor for overall survival in hepatocellular carcinoma treated with sorafenib in the SILIUS trial. *Liver Cancer* 2019;8:505-519.
68. Kudo M: Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies. *Liver Cancer* 2019;8:413-426, 2019.
69. Kudo M: A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: Initial lenvatinib therapy with subsequent selective TACE.

- Liver Cancer 2019;8:299-311.
70. Hiraoka A, Kumada T, Michitaka K, Kudo M: Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer 2019;8:312-325.
71. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M and the Liver Cancer Study Group of Japan: Prediction of prognosis of intermediate stage HCC patients – validation of tumor marker score in nationwide database in Japan. Liver Cancer 2019;8:403-411.
72. Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M: Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced asian cohort analysis. J Hepatol 2019;71:543-552.
73. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y: Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC Guidelines) a 2019 update. Hepatol Res 2019;49:1109-1113.
74. Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itabayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, Real-life Practice Experts for HCC (RELPEC) Study Group: Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma. Oncology 2019;97:277-285.
75. Kamata K, Watanabe T, Minaga K, Hara A, Yoshikawa T, Okamoto A, Yamao K, Takenaka M, Park AM, Kudo M: Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells. Int Immunol 2019;31:795-809.
76. Takenaka M, Kamata K, Kudo M: Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy by the intentional expansion method. Dig Endosc 2019;31:718.
77. Uchida S, Oiso N, Komeda Y, Kudo M, Kawada A: Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis. Eur J Dermatol 2019;29:444-445.
78. Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M: Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced asian cohort analysis (J Hepatol 71:543-552, 2019)”. J Hepatol 2019;71:1278.
79. Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, Nakagawa K, Kudo M: Gankyrin contributes to tumorigenesis and chemoresistance in sporadic colorectal cancer. Digestion 2019;100:192-200.
80. Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N, Liver Cancer Study Group of Japan: Treatment

- optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. Ann Surg 2019;270:121-130.
81. Tanaka H, Watanabe T, Nagai T, Minaga K, Kamata K, Komeda Y, Kudo M: Hepatic portal venous gas associated with Klebsiella oxytoca infection in the absence of preceding antibiotic treatment. Clin J Gastroenterol 2019;12:316-319.
 82. Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamura M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H: Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2019;54:742-751.
 83. Nishida N, Yamakawa M, Shiina T, Kudo M: Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology. Hepatol Int 2019;13:416-421.
 84. Okamoto A, Minaga K, Takenaka M, Yoshikawa T, Kamata K, Yamao K, Kudo M: A novel technique for stent dysfunction after endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting. Endoscopy 2019;51:E255-E256.
 85. Tanaka H, Kamata K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Sakurai T, Watanabe T, Nishida N, Chiba Y, Kitano M, Kudo M: Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. Dig Liver Dis 2019;51:1130-1134.
 86. Minami Y, Nishida N, Kudo M: Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy. Eur Radiol 2019;29:5045-5051.
 87. Watanabe T, Kamata K, Minaga K, Sakurai T, Yoshikawa T, Okamoto A, Komeda Y, Nagai T, Yamao K, Takenaka M, Hagiwara S, Nishida N, Kitani A, Tajima M, Fuss IJ, Kudo M, Strober W: RICK/RIP2 is a NOD2-independent nodal point of gut inflammation. Int Immunol 2019;31:669-683.
 88. Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-m multicenter analysis. Cancer Med 2019;8:3719-3728.
 89. Takenaka M, Minaga K, Yoshikawa T, Okamoto A, Nakai A, Omoto S, Kudo M: Novel concept using a plastic stent for endoscopic ultrasound-guided hepaticogastrostomy adjusting the length according to the patient's anatomy. Endoscopy 2019;51:E362-E363.
 90. Ogura T, Takenaka M, Shiomi H, Goto D, Tamura T, Hisa T, Kato H, Nishioka N, Minaga K, Masuda A, Onoyama T, Kudo M, Higuchi K, Kitano M: Long-term outcomes of EUS-guided transluminal stent deployment for benign biliary disease: Multicenter clinical experience (with videos). Endosc Ultrasound

- 2019;8:398-403.
91. Takenaka M, Yamao K, Kudo M: Can localized stenosis of the main pancreatic duct be a predictive factor for early detection of pancreatic cancer? Clin Endosc 2019;52:523-524.
 92. Evans TRJ, Kudo M, Finn RS, Han KH, Cheng AL, Ikeda M, Kraljevic S, Ren M, Dutcus CE, Piscaglia F, Sung MW: Correction: Urine protein: creatinine ratio vs 24-hour urine protein for proteinuria management: Analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. Brit J Cancer 121:625, 2019.
 93. Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman W, Chintharlapalli S, Abada P, Sherman M, Zhu AX: Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int 2019;39:2214-2229.
 94. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson P, Arai Y, on behalf of the TACTICS study group: Randomised, multicentre prospective trial of transarterial chemoembolization (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma. Gut 2019;[Epub ahead of print]
- 2) 学会発表
1. Kudo M, Ikeda M, Motomura K, Okusaka T, Kato N, Dutcus CE, Hisai T, Suzuki M, Ikezawa H, Iwata T, Kumada H, Kobayashi M: A phase 1b study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) (Study 117). 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 2. Alsina A, Kudo M, Vogel A, Cheng AL, Tak WY, Ryoo BY, Evans TRJ, Lopéz CL, Daniele B, Blanc JF, Ren M, Baldwin RL, Izumi N, Qin S, Finn RS: Subsequent anticancer procedures following first-line Lenvatinib (LEN): A post hoc analysis from the Phase 3 REFLECT study in unresectable hepatocellular carcinoma (uHCC). 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 3. Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee DW, Chen E, Siegel A, Ryoo BY: Phase 3 study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 4. Edeline J, Karwal M, Zhu AX, Finn RS, Cattan S, Ogasawara S, Verslype C, Zagonel V, Fartoux L, Vogel A, Rosmorduc O, Verset G, Chan SL, Knox J, Daniele B, Cheng AL, Goldmacher G, Jensen E, Siegel AB, Kudo M: RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro). 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 5. Kudo M, Chiba Y, Meyer T, Lencioni R, Llovet JM: Association of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic

- therapies: A systematic review and meta-analysis of randomized controlled trials. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
6. Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, Liang K, Shinozaki K, Wang C, Yoshikawa R, Abada P, Widau RC, Zhu AX: Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2). 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 7. Kudo M, Ueshima K, Ogawa C, Chiba Y: Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trial. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 8. Kudo M, Ueshima K, Chan SL, Aoki T, Hagiwara S, Minami Y, Ida H, Takenaka M, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Hiraoka A, Aikata H, Nishida N: Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 9. Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Know J, Daniele B, Gurary EB, Siegel AB, Jain L, Cheng AL, Zhu AX for the KEYNOTE-224 Investigators: Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 10. Edeline J, Yau T, Park JW, Kudo M, Han KH, Mathurin P, Merle P, Finn RS, Mueller T, Taylor F, Greenwood M, Begic D, Tschaika M, Yip C, Pranschke E, Cocks K, Thompson G, Blum S, Wisniewski T, Sangro B: CheckMate 459: Health-related quality of life in a randomized, multi-center phase 3 study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 11. He R, Yau T, Hsu C, Kang YK, Kim TY, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, El-Rayes BF, Acosta-Rivera M, Neely J, Shen Y, Tschaika M, El-Khoueiry AB: Nivolumab (NIVO) + Ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 12. Galle PR, Finn RS, Cheng AL, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder VV, Merle P, Kaseb AO, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M: Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs

- sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
13. Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Zagonel V, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Wang C, Ogburn K, Abada P, Widau RC, Zhu AX: Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 14. Vogel A, Frenette C, Sung MW, Daniele B, Baron AD, Chan SL, Blanc JF, Tamai T, Ren M, Lim HJ, Palmer DH, Takami Y, Kudo M: Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC). 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 15. Lim HY, Merle P, Finn RS, Frenette C, Masi G, Ikeda M, Zebger-Gong H, Fiala-Buskies S, Ozgurdal K, Kudo M, Qin S: Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: interim analysis of the prospective observational REFINE trial. 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 16. Reig M, Galle PR, Kudo M, Finn RS, Llovet JM, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX: Pattern of progression in advanced HCC treated with ramucirumab/placebo: results from two randomized phase III trials (REACH/REACH-2). 2020 Gastrointestinal Cancers Symposium (ASCO-GI 2020), San Francisco, USA, January 23-25, 2020.
 17. Kudo M, Ueshima K, Chan SL, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N: Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh a liver function: a multicenter propensity-score matched study. American Association for the Study of Liver Diseases (AASLD 2019), Boston, USA, November 8-12, 2019.
 18. Kudo M, Ueshima K, Nishida N: Objective response by mrecist is a prognostic factor for overall survival in unresectable hepatocellular carcinoma treated with systemic therapy: a systematic review and metaanalysis of randomized controlled trials. American Association for the Study of Liver Diseases (AASLD 2019), Boston, USA, November 8-12, 2019.
 19. Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Ishikawa T, Tsuji K, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K, Kudo M: Lenvatinib for unresectable hepatocellular carcinoma in real-world practice: a multicenter analysis of prognostic factors. American Association for the Study of Liver Diseases (AASLD 2019), Boston, USA, November 8-12, 2019.
 20. Nishida N, Yamakawa M, Shiina T, Kudo M:

- Development of AI-aided us diagnosis system of liver tumor using deep neural network. American Association for the Study of Liver Diseases (AASLD 2019), Boston, USA, November 8-12, 2019.
21. Ucnino K, Tateishi R, Fujiwara N, Moriyama M, Eguchi Y, Toyoda H, Ida Y, Karino Y, Kudo M, Chuma M, Takuma Y, Kaneko S, Kato N, Chayama K, Izumi N, Itoi T, Sakaida I, Komeda H, Umemura T, Ishikawa T, Nakamura M, Takaki A, Terai S, Ido A, Enomoto N, Yoshida H, Baba T, Torimura T, Hiasa Y, Ogawa C, Takehara T, Kumada T, Koike K: Clinical significance of tumor markers in surveillance for hepatocellular carcinoma in cirrhotic patients: a multicenter prospective cohort study in Japan. American Association for the Study of Liver Diseases (AASLD 2019), Boston, USA, November 8-12, 2019.
 22. Sangro B, Hsu C, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Neely J, Zhao H, Anderson J, Yau T: Checkmate 040: efficacy, hepatic safety, and biomarkers of Nivolumab + Ipilimumab combination therapy in patients with advanced hepatocellular carcinoma. American Association for the Study of Liver Diseases (AASLD 2019), Boston, USA, November 8-12, 2019.
 23. Kudo M, Zhu AX, Vogel A, Yau T, Zhou J, Chen E, Malhotra U, Siegel AB, Cheng AL: Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation. 34th Annual Meeting & Pre-Conference Programs (SITC 2019), Gaylord National Hotel & Convention Center, Maryland, USA, November 6-10, 2019.
 24. Bruix J, Reig M, Merle P, Kudo M, Meinhardt G, Zhang M, Ozgurdal K: Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial. European Society for Medical Oncology (ESMO 2019), Barcelona, Spain, September 27-October 1, 2019.
 25. Llovet JM, Kudo M, Cheng AL, Finn RS, Galle PR, Kaneko S, Meyer T, Qin S, Dutrus CE, Chen E, Dubrovsky L, Siegel AB, Zhu AX: LEAP-002: Phase 3 Study of First-Line Lenvatinib (len) Plus Pembrolizumab (pembro) for patients with advanced hepatocellular carcinoma (HCC). European Society for Medical Oncology (ESMO 2019), Barcelona, Spain, September 27-October 1, 2019.
 26. Kudo M, Okusaka T, Motomura K, Ikeda M, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Hirota S, Homma G, Chunxiao W, Shinozaki K, Yoshikawa R, Zhu AX: Ramucirumab (RAM) effect on albumin-bilirubin (ALBI) grade during treatment of Japanese patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib from two randomized phase 3 studies (REACH, REACH-2). European Society for Medical Oncology (ESMO 2019), Barcelona, Spain, September 27-October 1, 2019.
 27. Merle P, Kulkarni AS, Ryoo BY, Cheng AL, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist J, Chen E, Siegel AB, Zhu AX, Finn RS: Health-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma:

- KEYNOTE-240. European Society for Medical Oncology (ESMO 2019), Barcelona, Spain, September 27-October 1, 2019.
28. Llovet JM, Kudo M, Kang YK, Yen CJ, Finn RS, Gale PR, Assenat E, Motomura K, Okusaka T, Berg T, Hsu CH, Ikeda M, Hsu Y, Liang K, Widau R, Schelman W, O'Briain L, Gao L, Zhu AX: Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein: an exposure-response analysis. European Society for Medical Oncology (ESMO 2019), Barcelona, Spain, September 27-October 1, 2019.
 29. Kudo M, Galle PF, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomasek J, Borg C, Zagonel V, Morimoto M, Pracht M, Finn RS, Llovet J, Homma G, Jen MH, Shinozaki K, Yoshikawa R, Zhu AX: Efficacy and safety of ramucirumab for advanced hepatocellular carcinoma with elevated alpha-fetoprotein following sorafenib across age subgroups in two global Phase 3 trials (REACH, REACH-2). European Society for Medical Oncology (ESMO 2019), Barcelona, Spain, September 27-October 1, 2019.
 30. Zhu AX, Cheng AL, Vogel A, Yau T, Zhou J, Chen E, Malhotra U, Siegel AB, Kudo M: Pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) and complete radiological response following surgical resection or local ablation: Phase 3 KEYNOTE-937 trial. 13th Annual Conference International Liver Cancer Association (ILCA), Chicago, USA, September 20-22, 2019.
 31. Llovet JM, Kudo M, Cheng AL, Finn RS, Galle PR, Kaneko S, Meyer T, Qin S, Dutcus CE, Chen E, Dubrovsky L, Zhu AX: First-line combination therapy with lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma: Phase 3 Leap-002 study. 13th Annual Conference International Liver Cancer Association (ILCA), Chicago, USA, September 20-22, 2019.
 32. Evans TRJ, Kudo M, Cheng AL, Gomez-Martin C, Daniele B, Izumi N, Yamashita T, Tateishi R, Lim HJ, Chan SL, Rau KM, Alsina A, Misir S, Dutcus C, Sung MW: A post hoc analysis of neutrophil-lymphocyte ratios (NLR) in the REFLECT study: First-line lenvatinib (LEN) or sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC). 13th Annual Conference International Liver Cancer Association (ILCA), Chicago, USA, September 20-22, 2019.
 33. Sangro B, Kudo M, Qin S, Ren Z, Chan S, Erinjeri J, Arai Y, Mann H, Morgan S, Cohen G, Vlahovic G, Lencioni R: A Phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma (HCC): EMERALD-1. 13th Annual Conference International Liver Cancer Association (ILCA), Chicago, USA, September 20-22, 2019.
 34. Sangro B, Matilla A, Santoro A, Cubillo A, El-Khoueiry AB, El-Rayes B, Numata K, Itoh Y, Taylor F, Thompson G, Blum S, Wisniewski T, Baccan C, Kudo M: CheckMate 040: Health-related quality of life (HRQoL) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B status treated with nivolumab (NIVO). 13th Annual Conference International Liver Cancer Association (ILCA), Chicago, USA, September 20-22, 2019.
 35. El-Khoueiry AB, Hsu C, Kang YK, Kim TY, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, He AR, El-

- Rayes B, Acosta-Rivera M, Neely J, Shen Y, Baccan C, Yau T: Safety profile of Nivolumab (NIVO) plus Ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (HCC) in the CheckMate 040 study. 13th Annual Conference International Liver Cancer Association (ILCA), Chicago, USA, September 20-22, 2019.
36. Sangro B, Kudo M: A phase 3 randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab (D) or durvalumab plus bevacizumab (B) therapy in patients (Pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-1. American Society of Clinical Oncology Annual Meeting (ASCO 2019), Chicago, USA, May 31-June 4, 2019.
37. Llovet J, Kudo M, Cheng AL, Finn R, Galle P, Kaneko S, Meyer T, Qin S, Dutcus C, Chen E, Dubrovsky L, Zhu A: Lenvatinib plus pembrolizumab for the first-line treatment of patients with advanced hepatocellular carcinoma: Phase 3 LEAP-002 study. American Society of Clinical Oncology Annual Meeting (ASCO 2019), Chicago, USA, May 31-June 4, 2019.
38. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Neely J, Shen Y, Baccan C, Dela Cruz C, Hsu C: Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. American Society of Clinical Oncology Annual Meeting (ASCO 2019), Chicago, USA, May 31-June 4, 2019.
39. Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kuroasaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J: First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100). American Society of Clinical Oncology Annual Meeting (ASCO 2019), Chicago, USA, May 31-June 4, 2019.
40. Llovet JM, Yen CJ, Finn RS, Kang YK, Kudo M, Galle PR, Assenat E, Pracht M, Lim Y, Rau KM, Borg C, Hiriart JB, Daniele B, Berg T, Chung HC, Godinot N, Wang C, Hsu Y, Schelman WR, Zhu AX: Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): outcomes from two randomized phase 3 studies (REACH, REACH2). American Society of Clinical Oncology Annual Meeting (ASCO 2019), Chicago, USA, May 31-June 4, 2019.
41. Izumi N, Hasegawa K, Nishioka Y, Takayama T, Yamanaka N, Kudo M, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N: A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma (SURF trial). American Society of Clinical Oncology Annual Meeting (ASCO 2019), Chicago, USA, May 31-June 4, 2019.
42. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder VV, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox JJ, Daniele B, Ebbinghaus S, Chen E, Siegel AB, Zhu AX, Cheng AL, for the KEYNOTE-240 Investigators: Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). American

Society of Clinical Oncology Annual Meeting
(ASCO 2019), Chicago, USA, May 31-June 4,
2019.

H. 知的財産権の出願・登録状況(予定を含む)

- 1) 特許取得:なし
- 2) 実用新案登録:なし
- 3) その他:なし